Stockscreener 앱 받기
4.39
1.79%
-0.08
시간 외 거래:
4.44
0.05
+1.14%
전일 마감가:
$4.47
열려 있는:
$4.4
하루 거래량:
3.06M
Relative Volume:
1.29
시가총액:
$476.62M
수익:
-
순이익/손실:
$-223.12M
주가수익비율:
-2.1846
EPS:
-2.0095
순현금흐름:
$-190.49M
1주 성능:
-10.77%
1개월 성능:
+17.38%
6개월 성능:
+43.00%
1년 성능:
-48.11%
1일 변동 폭
$4.17
$4.48
1주일 범위
$4.17
$5.1199
52주 변동 폭
$2.19
$8.80
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
명칭
Rocket Pharmaceuticals Inc
전화
646-440-9100
주소
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
4.39 | 485.30M | 0 | -223.12M | -190.49M | -2.0095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-08-20 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-30 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-05-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-28 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-28 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | 다운그레이드 | Needham | Buy → Hold |
| 2025-05-27 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-30 | 개시 | Wedbush | Outperform |
| 2024-12-18 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 개시 | Morgan Stanley | Overweight |
| 2022-11-08 | 개시 | Canaccord Genuity | Buy |
| 2022-11-01 | 개시 | BTIG Research | Buy |
| 2022-07-08 | 개시 | Raymond James | Outperform |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2021-02-18 | 개시 | Needham | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 개시 | JP Morgan | Overweight |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2019-11-06 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-26 | 개시 | Piper Jaffray | Overweight |
| 2019-04-23 | 개시 | Robert W. Baird | Outperform |
| 2019-03-15 | 개시 | BofA/Merrill | Buy |
| 2019-02-05 | 개시 | Oppenheimer | Outperform |
| 2018-09-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-10 | 개시 | William Blair | Outperform |
모두보기
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
Aug Drivers: Can Rocket Pharmaceuticals Inc expand into new markets2026 Bull vs Bear & Expert Curated Trade Setups - baoquankhu1.vn
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 4.4%Here's What Happened - MarketBeat
Rocket Pharmaceuticals to present LAD I advances at primary immune deficiency workshop - Traders Union
Morgan Stanley names Rocket Pharmaceuticals (RCKT) as key beneficiary of 2026 biotech sector recovery - MSN
RCKT's Q4 loss narrower than estimated, pipeline in focus - MSN
Suvretta Capital Management LLC Cuts Position in Rocket Pharmaceuticals, Inc. $RCKT - MarketBeat
Rocket Pharmaceuticals, Inc. $RCKT Holdings Trimmed by Prosight Management LP - MarketBeat
Chart Watch: Is Rocket Pharmaceuticals Inc forming a bullish divergence2026 Levels & Fast Gain Swing Alerts - baoquankhu1.vn
Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish - MSN
Insider Buy: Is Rocket Pharmaceuticals Inc part of any ETF2026 Earnings & AI Enhanced Trading Alerts - baoquankhu1.vn
Rocket Pharmaceuticals Enters New Sales Agreement with Cantor Fitzgerald, Terminates Prior Equity Offering Arrangement - Minichart
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 4.8%Should You Sell? - MarketBeat
Rocket Pharmaceuticals Launches New $100M At-The-Market Program - TipRanks
[EFFECT] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Rocket Pharmaceuticals enters $100 million at-the-market offering agreement - Investing.com
Rocket Pharmaceuticals enters $100 million at-the-market offering agreement By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals (RCKT) Launches $100 Million Stock Offeri - GuruFocus
Rocket Pharmaceuticals Launches $100 Million ATM Offering With Cantor Fitzgerald - TradingView
According to the latest filing with the U.S. Securities and Exchange Commission, biotechnology company Rocket Pharmaceuticals, Inc. has officially signed an equity sales agreement with renowned financial institution Cantor Fitzgerald & Co. - Bitget
Rocket Pharmaceuticals (RCKT) launches $100M at-the-market stock offering with Cantor - Stock Titan
Form 424B5 ROCKET PHARMACEUTICALS, - StreetInsider
Rocket Pharmaceuticals (RCKT) launches up to $100M ATM offering with Cantor - Stock Titan
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 5.4%What's Next? - MarketBeat
UniQure leads genetic medicine biotech rally after news of Prasad’s exit - BioPharma Dive
Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to Sell at Wall Street Zen - MarketBeat
Short Covering: Is Rocket Pharmaceuticals Inc Equity Warrant attractive for institutional investorsDollar Strength & Low Drawdown Investment Ideas - baoquankhu1.vn
Weekly Recap: Is Rocket Pharmaceuticals Inc showing insider buyingQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn
RCKT SEC FilingsRocket Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
RCKT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Canaccord Genuity Sticks to Their Buy Rating for Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Rocket gene therapy among at least 7 PDUFA dates at FDA in March - BioCentury
Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances - Yahoo! Finance Canada
Rocket Pharmaceuticals (NASDAQ: RCKT) files $400M shelf to raise capital - Stock Titan
Goldman Sachs Maintains 'Sell' Rating on RCKT, Raises Price Targ - GuruFocus
The Goldman Sachs Group Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock - MarketBeat
Brokers Set Expectations for RCKT FY2026 Earnings - MarketBeat
Rocket Pharmaceuticals: Advancing Gene Therapy Pipeline and High-Confidence KRESLADI Approval Drive Buy Rating - TipRanks
Chart Watch: Is Rocket Pharmaceuticals Inc showing insider buying2025 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn
Lifesci Capital Upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) to Strong-Buy - MarketBeat
Cantor Fitzgerald Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - The Globe and Mail
Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring A 71% Upside Potential - DirectorsTalk Interviews
Rocket Pharmaceuticals Q4 2025 Financial Report & Annual ResultsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 14.3% Following Earnings Beat - MarketBeat
Cantor Fitzgerald Raises Rocket Pharmaceuticals (RCKT) Price Tar - GuruFocus
Cantor Fitzgerald Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock - MarketBeat
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Hold" from Analysts - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Rocket Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Rocket Pharmaceuticals: Q4 Earnings Snapshot - theheraldreview.com
Rocket Pharmaceuticals Inc (RCKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):